Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2022 Earnings Call Transcript

Panna Sharma: But also in those studies, we did spironolactone alone and it showed no effect on the tumor.

Kishor Bhatia: Yes. Spironolactone alone did not show any effect. That’s right.

Michael King: I just wonder if you have to show it in many of the small number of patients, but I’ll leave that for now. And then just on Starlight, is there still gating items? Maybe just sort of the documentation for the Phase 1 trial that would have you somewhat behind the studies of LP-184. If I read your slide correctly, show that Starlight IND would be a little bit later this year behind the anticipated one for 184.

Panna Sharma: Starlight, we’d just pick up after the 1a. So, Starlight, that would pick up in Phase 1b or 2a. So, the 1a is going to be multi-tumor. And once we have the MTD and the MTD-1, then we’ll probably in that Phase 1a have certain CNS cancer patients. And once we’ve established that MTD, then we can enrich

Michael King: Turning it over to Starlight. I got it.

Nicole Leber: One more question we have is, does the expected increased cash burn rate factor into our projections through 2025?

David Margrave: Yes, we’re taking that into account when we’re stating that our current financial position carries us into 2025.

Nicole Leber: Okay. And with that, that will conclude our webcast for today. Thank you all for joining and we’ll hope to see you over at our KOL webinar tomorrow. Thank you, everyone.